Korea-Beauty on Korea Invest Insights

Who Owns Rejuran? PharmaResearch and Korea's Skin-Booster Platform

Mon, 27 Apr 2026 23:30:00 +0900

📚 See the Olive Young, PharmaResearch and K-Beauty investment hub for the full thread across Rejuran / PharmaResearch, Olive Young, CJ and APR / Medicube.

TL;DR

Rejuran is owned by PharmaResearch Co., Ltd. (KOSDAQ: 214450), a Korean medical-aesthetics specialty company. Rejuran is a brand; the underlying technology is PharmaResearch’s proprietary PN (Polynucleotide) / PDRN platform, derived from purified salmon DNA fragments.
PharmaResearch is the only listed public proxy for the polynucleotide skin-booster category. There is no separate Rejuran ticker — buying Rejuran exposure means buying PharmaResearch.
The Rejuran franchise is now multi-product, multi-indication, multi-region: Rejuran Healer / HB / Eye / S, distributed across 50+ countries with active expansion in Thailand, Indonesia, Vietnam, Malaysia, the Middle East, Brazil, and the EU. China and US entry are the high-value pending catalysts.
Competitive frame: Rejuran is not a botulinum toxin (Hugel, Medytox, Daewoong) and not a hyaluronic-acid filler (Galderma Restylane, AbbVie Juvederm). It defines its own subcategory — regenerative skin-booster via salmon-DNA polynucleotide — and sits closer to Galderma’s Sunekos / Croma’s pipeline in Western markets.
Investor framing: PharmaResearch is a specialty-platform compounder with a single-flagship-brand concentration risk. Bulls focus on PN-platform extensibility and ex-Korea growth runway. Bears focus on competitive entrants (Korean and Western) and pricing pressure as the polynucleotide category gets crowded.

1. The Direct Answer

Rejuran is manufactured, marketed, and licensed globally by PharmaResearch Co., Ltd. (KOSDAQ: 214450).

Item	Value
Brand	Rejuran (리쥬란)
Manufacturer / Owner	PharmaResearch Co., Ltd.
Listing	KOSDAQ: 214450
Headquarters	Gangnam-gu, Seoul, South Korea
Core platform	PN (Polynucleotide) / PDRN, salmon-DNA-derived
First Rejuran approval (Korea)	Original Rejuran Healer launched in Korea, with subsequent line extensions
Brand variants	Rejuran Healer, Rejuran HB (Hydrobalance), Rejuran Eye, Rejuran S (Scar)
Other PharmaResearch businesses	Conjuran (PN injectable solution for joints), aesthetic devices, dermo-cosmetic line, distribution arms

Important framing: search-engine queries like “who owns rejuran” and “rejuran parent company” land here because Rejuran has stronger consumer brand recognition (especially in Southeast Asia and the Middle East) than the company that makes it. Most clinic patients and end consumers know “Rejuran” but not “PharmaResearch.”

For investors, the relevant identity is the parent. PharmaResearch is the public ticker; Rejuran is its flagship product brand.

2. The Platform Behind the Brand: PN / PDRN from Salmon DNA

What Rejuran actually is, technically:

PDRN = Polydeoxyribonucleotide. PN = Polynucleotide. Both refer to fragmented DNA polymers.
Rejuran’s active ingredient is purified, fragmented salmon DNA polynucleotides processed to a defined molecular-weight range.
Mechanism (publicly stated by the company and dermatology literature): polynucleotides are believed to act as substrates for adenosine A2A receptors, promote fibroblast activity, modulate inflammation, and support collagen / elastin synthesis at the dermal layer.
Clinical positioning: regenerative skin booster (not a filler that adds volume; not a neurotoxin that paralyzes muscle). Used for skin-quality improvement — texture, fine lines, hydration, scars, post-acne, peri-orbital area.

The strategic implication for investors:

PharmaResearch is vertically integrated on the PN platform — raw material handling, purification, formulation, sterile injectable manufacturing, regulatory dossiers, brand marketing, clinical-channel education.
The platform is extensible. Rejuran for face is one application. Conjuran for joints is another. Future indications (hair, scalp, post-procedural recovery, scar, surgical wound) sit on the same upstream chemistry.
Brand vs. ingredient is the value-capture question. PDRN as a category exists outside PharmaResearch — Italian companies (Mastelli’s “PDRN” formulations) and other entrants exist. What PharmaResearch owns is Rejuran as a brand-trust asset and the manufacturing-quality-system reputation that has made Rejuran the defining brand in Korea, Southeast Asia, and parts of MENA.

3. The Rejuran Product Family

A practical map for global readers who encounter Rejuran in clinics:

Variant	Indication / Use	Notes
Rejuran Healer	Original / signature; full-face skin booster	Most commonly referenced “Rejuran” in clinics
Rejuran HB (Hydrobalance)	Adds HA component for hydration emphasis	Often used for sensitive / dehydrated skin
Rejuran Eye	Periorbital / under-eye area	Specifically formulated for thin under-eye skin
Rejuran S	Scar / atrophic skin	Targeting acne scars, surgical scars

In some markets, additional SKUs and bundles exist via local distributors. The brand also extends into dermo-cosmetic / cosmeceutical lines (e.g., Rejuran Healer Skin Care series in select markets), which are non-injectable home-use products under brand license.

For investor due diligence: revenue mix between Rejuran (face) / Conjuran (joint) / cosmeceutical / device & other has historically been weighted heavily toward Rejuran (face), with Conjuran and cosmeceutical as growth optionality.

4. PharmaResearch as the Only Listed Public Proxy

Investors looking for Rejuran exposure have one and only one listed entry point: PharmaResearch (214450.KS / KOSDAQ).

What you get when you own PharmaResearch:

Bucket	What it is
Rejuran face franchise	Original Healer + HB + Eye + S, domestic + international distribution
Conjuran joint franchise	PN-based intra-articular injectable for osteoarthritis-adjacent indications
Cosmeceutical / dermo-cosmetic	Brand-extension home-use products
Aesthetic devices / equipment	Distribution and proprietary device lines
B2B / R&D / licensing	Out-licensing of PN formulations, clinical pipeline

Why no separate Rejuran ticker exists:

PharmaResearch has historically chosen to keep Rejuran inside the parent company rather than spin it out. The advantage for the parent: Rejuran is the cash-generative flagship, and consolidating its margin inside PharmaResearch’s P&L underwrites the company’s overall growth story. A spinout has been speculated periodically, but as of April 2026 there is no public announcement of such a transaction.

General financial-profile shape (industry-tracked levels, directional):

Revenue growth: high-teens to high-20s % YoY range across multiple recent years, driven by Rejuran international plus Conjuran ramp.
Operating margin: high-teens to mid-20s % range — characteristic of a specialty-injectable manufacturer with strong brand pricing power and modest sales-and-marketing intensity (clinic-channel pull rather than mass-media push).
Dividend: modest payout; growth-stage capital allocation has prioritized capacity, R&D, and selective overseas-market investment over yield.
Cash position: net cash historically; capex weight has stepped up alongside international expansion.

(Specific quarterly revenue, OPM, and net-cash levels should be cross-checked against the company’s most recent disclosure on DART or its investor-relations site before any sizing decision.)

5. Global Expansion — Where Rejuran Is Actually Selling

The most underappreciated piece of the Rejuran story for non-Korean investors is how international the franchise has already become.

Active commercial markets (illustrative; via local distributors and clinic-channel adoption):

Southeast Asia — Thailand, Singapore, Malaysia, Indonesia, Vietnam, Philippines. Thailand has been a particular standout, with strong clinic-channel adoption and high consumer brand awareness.
Middle East / Gulf — UAE, Saudi Arabia (regulatory pathway by emirate / authority), with Dubai and Riyadh aesthetic clinics being early adopters.
South Asia — India (regulatory entry).
Australia / NZ — selected clinic networks.
Latin America — Brazil (the largest medical-aesthetics market in LatAm), Mexico.
Europe — selected EU markets via CE-marked formulations.
Russia / CIS — historically active, with current dynamics affected by macro / sanctions environment.

Pending high-value catalysts:

China — the single biggest pending catalyst. The Chinese medical-aesthetics market is the largest ex-US opportunity and would be transformational for any polynucleotide-platform owner if formal NMPA pathways open broadly to imported PN injectables. Local dynamics include parallel imports, daigou (personal-import) flows, and regulatory tightening cycles. PharmaResearch has pursued formal entry; the timing and final approval scope remain partially uncertain.
United States — the highest-value but most regulatory-intense pathway. The US FDA pathway for an injectable like Rejuran (whether as a device or biologic, depending on classification) is multi-year and capital-intensive. A successful US approval would dramatically re-rate the franchise globally because it would also serve as a gold-standard regulatory reference for other markets.
Western Europe full coverage — current EU presence is selective; deeper penetration with country-by-country distributor agreements remains incremental upside.

The current revenue mix already meaningfully weights international, and the trajectory is toward further international over domestic as the Korean market matures and global clinic adoption scales.

6. Competitive Landscape — What Rejuran Is and Isn’t

Investors familiar with Korean aesthetics often try to map Rejuran against the more famous botulinum toxin and hyaluronic-acid filler names. The mapping is wrong, and getting the categorization right is essential to understanding the thesis.

Category	Mechanism	Listed Korean names	Rejuran vs. these
Botulinum toxin	Neuromuscular blockade; relaxes wrinkles	Hugel (145020.KS), Medytox (086900.KS), Daewoong (069620.KS)	Different category. Rejuran does not paralyze muscle.
Hyaluronic-acid filler	Volumizes; replaces lost soft tissue	LG Chem (Yvoire), Humedix, etc.	Different category. Rejuran does not add volume.
Skin-quality / regenerative booster	Stimulates dermal regeneration	PharmaResearch (Rejuran), plus newer Korean PN entrants	This is Rejuran’s category.
Aesthetic device	RF / HIFU / laser-based skin tightening	Classys (214150.KS), Lutronic, Wontech	Adjacent. Often used in combination treatments with Rejuran.
Cosmeceutical	Topical home-use	AmorePacific, LG H&H	Adjacent. Brand-extension space.

Western analogues:

Galderma’s Sunekos and the broader European polynucleotide / amino-acid skin-booster category — most directly comparable Western-market product class.
Croma Pharma (Austria) — pipeline activity in PN / regenerative skin boosters.
Some Italian PDRN brands (e.g., Mastelli) — more pharmaceutical-positioning than aesthetic-clinic positioning.
Galderma’s Restylane Skinboosters (HA-based, different mechanism, but competing for the “skin quality” treatment slot in clinics).

Korean competitive entry

The Korean polynucleotide subcategory has begun to attract additional entrants attempting to compete with Rejuran on price or formulation differentiation. This is the most important medium-term competitive watch-point. PharmaResearch’s defensibility rests on:

Brand trust — Rejuran is the most-known PN brand in Korea, Southeast Asia, and significant parts of MENA.
Manufacturing quality — sterile injectable manufacturing under regulated quality systems is hard to replicate.
Clinical-channel relationships — KOL networks, training, clinic-loyalty programs.
Regulatory dossiers — international approvals are a multi-year asset that competitors cannot shortcut.

Bears point to PN as a category eventually being commoditized by multiple entrants, with margin compression following. Bulls point to brand-trust-led pricing power persisting in a clinic-channel-dependent category similar to how botulinum-toxin brands have historically held premium positioning despite molecular near-equivalence among entrants.

7. Investor Framework — Bull / Bear / Risks

Bull case

PN platform extensibility. Rejuran (face) → Conjuran (joint) → potential further indications → potential out-licensing.
International revenue runway. Korean market alone cannot grow at the trajectory observed; the international base is now meaningful and continues to expand by region.
China optionality. A successful regulated entry materially changes the franchise’s TAM math.
US optionality. A regulated US pathway, if achieved, is a global reference standard and a dramatic re-rating event.
Brand defensibility. Rejuran is one of the strongest aesthetic-injectable brands in Asia and is increasingly competitive globally.
K-aesthetics tailwind. Inbound medical tourism to Korea, Korean-clinic prestige globally, and K-beauty / K-pop cultural halos all support PharmaResearch’s brand premium.

Bear case

Single-flagship concentration. Rejuran (face) is a large share of revenue; any pricing or competitive event affecting the flagship hits the parent disproportionately.
Korean PN competition. New domestic entrants targeting Rejuran’s price point can compress margins faster than international growth offsets.
Regulatory friction. Any negative regulatory event in a major market — a label restriction, a competitor injection-quality issue spilling over to category sentiment, China NMPA scope changes — can stall momentum.
Western progress slow. US and broader EU regulatory pathways are slow and expensive; a multi-year delay against expectations would compress the long-term TAM math.
Counterfeit / parallel-import dilution. In high-demand markets like China and Vietnam, parallel-import and counterfeit risks affect both brand integrity and reported revenue.
Aesthetic-cycle macro. Discretionary aesthetic procedures are not recession-immune; severe global consumer-spending downturns affect clinic volumes.

Material risks to monitor

Quarterly disclosure of Korea vs. ex-Korea revenue mix and major-region growth.
China regulatory updates (NMPA approval scope, distributor configurations).
US clinical / regulatory milestones if and when public.
Margin trend — early signs of price competition in domestic Korean PN.
Counterfeit / parallel-import disclosures in major Asian markets.
Corporate-action / capital-allocation news (M&A, R&D in-licensing, possible spinout discussions).

8. Cross-Reference — How Rejuran / PharmaResearch Fits the Broader K-Aesthetics Stack

For investors building a K-aesthetics basket (rather than a single-name PharmaResearch position), the framework looks like this:

Slot in basket	Listed name(s)	Role
Botulinum toxin	Hugel (145020.KS), Medytox (086900.KS), Daewoong Pharm (069620.KS)	Core injectable category, US / China optionality
Hyaluronic-acid filler	Humedix, LG Chem (Yvoire)	Filler exposure
Polynucleotide skin booster	PharmaResearch (214450.KS)	This post
Aesthetic devices	Classys (214150.KS), Lutronic	RF / HIFU / laser-based
K-beauty cosmetics (premium brands)	AmorePacific (090430.KS), LG H&H (051900.KS)	Topical premium brands
K-beauty ODM / manufacturing	Cosmax (192820.KS), Kolmar Korea (161890.KS), Kolmar BNH (200130.KS)	Indie / private-label upstream
K-beauty retail / distribution	CJ Corporation (000120.KS) — for indirect Olive Young exposure	Channel layer

PharmaResearch occupies the regenerative injectable slot in this basket. It does not substitute for botulinum-toxin exposure or filler exposure; it complements them.

9. Final Read

The single-line answer to the search-engine query: Rejuran is owned by PharmaResearch Co., Ltd., listed on the Korean KOSDAQ as ticker 214450. There is no separate Rejuran ticker.

The investor-framing answer: Rejuran is the consumer face of a deeper asset — PharmaResearch’s PN / PDRN platform — which the company has converted into a global injectable franchise spanning Southeast Asia, the Middle East, Latin America, and selected European markets, with China and the US as the high-value pending catalysts.

The category-positioning answer: Rejuran is not a botulinum toxin and not a filler. It defines its own regenerative-skin-booster category, which makes it a portfolio-additive — not a portfolio-substitute — exposure within a K-aesthetics basket.

For global readers searching “who owns Rejuran” or “rejuran parent company,” the practical takeaway is that the brand and the parent are tightly linked, and the cleanest route to participate in the Rejuran growth story as an investor is to evaluate PharmaResearch (214450.KS) on its own platform-and-international-expansion merits.

Appendix — Evidence Tier

[Fact]

Rejuran is a brand of polynucleotide-based skin-booster injectables.
Rejuran is owned, manufactured, and globally licensed by PharmaResearch Co., Ltd.
PharmaResearch is listed on the Korean KOSDAQ market under ticker 214450.
PharmaResearch’s flagship platform is its PN (Polynucleotide) / PDRN technology, derived from purified salmon DNA.
The Rejuran product family includes Rejuran Healer, Rejuran HB, Rejuran Eye, and Rejuran S, with additional SKUs and brand extensions in select markets.
Conjuran is PharmaResearch’s PN-platform product for joint applications, distinct from Rejuran’s aesthetic/dermatologic positioning.
Rejuran is distributed in many international markets via local distributors and clinic networks.
Hugel, Medytox, and Daewoong Pharm are listed Korean botulinum-toxin players; PharmaResearch is not in the same category.
Classys and Lutronic are listed Korean aesthetic-device companies adjacent to PharmaResearch’s clinic-channel ecosystem.

[Inference]

PharmaResearch is currently the only listed public proxy for the polynucleotide skin-booster subcategory.
PharmaResearch’s revenue trajectory has been increasingly driven by ex-Korea growth.
Brand defensibility, manufacturing-quality reputation, and international regulatory dossiers create a meaningful moat against Korean PN entrants attempting price-led competition.
China and US regulatory progress are the highest-value pending catalysts for the franchise.

[Speculation]

A formal Rejuran spin-out is plausible but not currently announced; if it occurred, it would create a more direct public proxy.
US FDA approval, if achieved, would likely act as a global reference standard and re-rate the franchise meaningfully across all markets.
Korean PN competitive entrants will continue to increase, but Rejuran’s brand position and clinical-channel anchoring should sustain a premium for a multi-year horizon.

[Blocked]

Exact most-recent quarterly Korea-vs-international revenue mix.
Specific China NMPA approval scope and timeline.
Specific US FDA pathway classification and milestone status.
Detailed gross-margin breakdown by product line (Rejuran vs Conjuran vs cosmeceutical vs device).

Disclaimer: For research and information purposes only. Not investment advice. Names cited are for analytical illustration; readers should perform their own due diligence and consult licensed advisors before any investment decision.

Is Olive Young Publicly Traded? How to Invest in K-Beauty Exposure

Mon, 27 Apr 2026 22:00:00 +0900

📚 See the Olive Young, PharmaResearch and K-Beauty investment hub for the full thread across Olive Young’s listing status, CJ indirect exposure, Rejuran / PharmaResearch and APR / Medicube.

TL;DR

Olive Young is not publicly traded. It is a private subsidiary of the CJ Group, formally CJ Olive Young Corp., which separated from CJ Olive Networks in 2019.
The cleanest indirect proxy is CJ Corporation (000120.KS) — the holding company that owns roughly 51.2% of CJ Olive Young. The Lee family (chairman Lee Jay-hyun’s children) holds another ~22% directly, with the remainder held by financial investors after a 2021 pre-IPO round.
CJ CheilJedang (097950.KS) is not a direct Olive Young play. It is the group’s food / bio business (Bibigo, lysine, methionine). The cross-link is “same group, different listed entity.”
Olive Young’s IPO has been deferred at least twice (cancelled 2022; subsequent strategic review). As of April 2026 there is no confirmed listing date.
For investors who want real K-beauty exposure (rather than a holdco-discounted slice), the better-aligned listed names are AmorePacific, LG H&H, Cosmax, Kolmar Korea, and selected ODM/brand specialists. Full framework below.

1. The Direct Answer

No, Olive Young is not listed on any stock exchange.

Search-engine queries like “is olive young publicly traded” or “olive young stock” land here for a structural reason — the company has the brand recognition of a public stock (Korea’s #1 H&B retailer, US Amazon expansion, viral on TikTok) but the legal status of a private subsidiary. Foreign retail investors looking for a ticker don’t find one and conclude either (a) “I’ll buy the parent” or (b) “I’ll buy a different K-beauty name.” Both paths have nuance.

Corporate identity:

Item	Value
Legal name	CJ Olive Young Corp. (CJ 올리브영 주식회사)
Ultimate parent group	CJ Group
Direct parent (controlling)	CJ Corporation (000120.KS)
Spin-off lineage	Carved out from CJ Olive Networks in 2019
Listed?	No
Most recent IPO attempt	2022 (withdrawn)
Capital event since	2021 pre-IPO round (Glenwood / financial investors); subsequent secondary share-sale discussions reported around 2023–2024

2. Why the Question Keeps Coming Up

Olive Young grew from a domestic chain into a global K-beauty distribution platform in the post-COVID window:

Domestic dominance after rivals (Lalavla / GS, Lohbs / Lotte) effectively exited Korea’s H&B chain category — Olive Young is now the de-facto national H&B utility.
Inbound-tourist halo — the Myeongdong flagship became a mandatory stop for Chinese, Japanese, and Southeast Asian travelers; tax-refund volume surged.
Cross-border digital channel — globalolive.young.co.kr ships to 150+ countries, and the brand actively cross-promotes on TikTok / Instagram in the US, Japan, Vietnam, and Indonesia.
PB / exclusive-brand engine — Olive Young is no longer a pure retailer; it is also a brand incubator (e.g., wakemake, Bring Green, Round A’Round) and an exclusive-launch channel for emerging K-beauty brands wanting domestic shelf-test before global scale-up.

This is exactly the profile US / EU / SEA retail investors want to own. The friction: there is no Olive Young ticker.

3. The Cleanest Indirect Proxy: CJ Corporation (000120.KS)

CJ Corporation is the listed holding company at the top of the CJ Group. Its ownership in CJ Olive Young is the largest single block.

Approximate cap-table (publicly reported levels)

Holder	Stake (approx.)
CJ Corporation (000120.KS)	~51.2%
Lee Sun-ho (chairman’s son)	~11.0%
Lee Kyung-hoo (chairman’s daughter)	~4.6%
Glenwood / Korean financial investors (2021 pre-IPO round)	balance, with secondary trades since

(Stake percentages are reported levels and have shifted with each capital event; the directional fact — CJ Corp majority + Lee-family meaningful, financial-investor float — is stable.)

What CJ Corp actually owns (beyond Olive Young)

CJ Corp is a holdco. Its NAV is the sum of stakes in:

CJ CheilJedang (food / bio — Bibigo, fermented amino acids)
CJ ENM (entertainment — TVING, Mnet, Studio Dragon)
CJ Logistics
CJ Olive Young (Korea’s #1 H&B)
CJ Freshway (B2B food)
Smaller affiliates

So owning CJ Corp gives you a holdco-discounted slice of Olive Young plus everything else. That is both the appeal and the limitation.

Holdco discount math (illustrative)

If you wanted only Olive Young exposure, CJ Corp gives you:

Effective Olive Young exposure per ₩ of CJ Corp
= CJ Corp ownership in OY (~51.2%)
 × your ownership in CJ Corp
 × (1 − holdco discount)

Korean holdcos historically trade at a 30–50% discount to NAV. So even if Olive Young’s standalone equity value rises, your CJ Corp share captures only a discounted portion. Conversely, when the market re-rates Korean holdcos (e.g., during a Value-Up or governance-reform cycle — see April 2026 “Korea Outperformance” backdrop), CJ Corp can outperform Olive Young’s underlying growth via discount compression.

4. Why CJ CheilJedang Is Not a Direct Olive Young Play

CJ CheilJedang (097950.KS) is the most-googled CJ-affiliate in English, partly because of Bibigo’s US grocery footprint. It is a separate listed entity with no operational tie to Olive Young.

Aspect	CJ Corporation	CJ CheilJedang	CJ Olive Young
Listed?	Yes (000120.KS)	Yes (097950.KS)	No
Business	Holdco	Food / bio	H&B retail + brand
Direct ownership of OY	~51.2%	None operational	—
Useful for OY exposure?	Yes (indirect)	No	—

If a search-engine result tells you “buy CJ CheilJedang to get Olive Young exposure,” that’s wrong. CheilJedang is a food + bioscience company with its own thesis (lysine pricing, Bibigo US, methionine cycle).

5. Olive Young IPO History — Why It Hasn’t Happened Yet

A short timeline:

2019 — CJ Olive Young separates from CJ Olive Networks via spin-off, becomes its own corporate entity.
2021 — Pre-IPO round closes; financial investors (Glenwood-led consortium reported) take a minority stake; valuation discussions reportedly in the ₩1.5–1.8T range at the time.
2022 — Olive Young files for KOSPI listing. The deal is withdrawn citing weak IPO market conditions and valuation gap.
2023–2024 — Reports surface periodically of strategic options including a block-sale of the Lee-family stake, an Olive Young secondary offering, or a renewed IPO timing window. Some reports mentioned Goldman Sachs as advisor on capital-structure options. None of these culminated in a confirmed listing.
2026 (current) — Olive Young remains private. Operating numbers continue to grow strongly (revenue past ₩4T-class, double-digit OPM range). No confirmed listing date.

Why the delay matters for investors

Valuation has likely moved up. The 2021 pre-IPO mark of ₩1.5–1.8T is dated. Every additional year of double-digit revenue + margin expansion lifts the implied IPO valuation, which expands CJ Corp’s NAV — but only realizes if the market re-rates the holdco.
Successor-generation ownership matters. Lee Sun-ho’s ~11% personal stake is non-trivial. Any future IPO + post-IPO secondary creates a path to family-wealth crystallization that is a structural incentive for CJ Group to push the listing eventually.
Korean Value-Up backdrop. With Korean governance reform and the broader 2026 re-rating story (KOSPI YTD strength, holdco discount compression), the window for Olive Young IPO has materially improved vs. the 2022 environment.

Implication: the right way to read CJ Corp today is “holdco that owns a yet-to-IPO crown-jewel asset that is roughly 50% bigger and structurally better-positioned than at the last failed IPO attempt.”

6. The Better-Aligned K-Beauty Listed Names

If your actual goal is K-beauty exposure rather than “Olive Young specifically,” you have cleaner options. Five buckets:

Bucket A — Brand Heavyweights

Ticker	Company	Profile
090430.KS	AmorePacific	Sulwhasoo, Laneige, Innisfree. China-recovery + US/JP rotation.
051900.KS	LG H&H	Whoo, Su:m37°, Belif. Premium duty-free + diversified into beverage/HBA.

These are the legacy K-beauty incumbents. They give you direct premium-brand exposure without the holdco discount, but they also carry China-tourism beta that has been volatile.

Bucket B — Indie & Mass-Market Brands (Listed)

Ticker	Company	Profile
214150.KS	ClassysB / various indies	Skin device + cosmetic combos.
214450.KS	Pharmaresearch	Rejuran (skin booster). Crossover into K-beauty halo.

The indie / clinical-skincare crossover names tend to ride US + Japan TikTok cycles harder than the heritage brands.

Bucket C — ODM / Manufacturing Backbone

Ticker	Company	Profile
192820.KS	Cosmax	Global K-beauty ODM. Manufacturer behind many indie / private-label brands sold through Olive Young.
161890.KS	Kolmar Korea	The other half of the K-beauty ODM duopoly.

ODMs are often the purest K-beauty wave play — they manufacture for whoever wins the brand cycle, including Olive Young’s PB lines and indie brands sold on Olive Young shelves. Lower brand-risk, higher capacity-utilization sensitivity.

Bucket D — Brand-Holding via Strategic M&A

COSRX — Acquired by Kolmar BNH (200130.KS) in 2021; Kolmar BNH is a listed proxy for the COSRX US-Amazon-bestseller story.
Other selective brand acquisitions by listed Korean cosmetics groups occur regularly; track via DART filings.

Bucket E — Holdco Indirects (where Olive Young actually sits)

CJ Corporation (000120.KS) — the Olive Young holdco proxy itself.

Quick decision framework

Your goal	Best path
Pure Olive Young upside	CJ Corporation (000120.KS) + accept holdco discount, watch for IPO catalyst
K-beauty premium-brand cycle	AmorePacific / LG H&H
Indie + US TikTok cycle	Cosmax / Kolmar Korea (ODMs)
US-Amazon-bestseller specifically	Kolmar BNH (COSRX)
Diversified K-beauty basket	Equal-weight across AmorePacific, LG H&H, Cosmax, Kolmar Korea + small CJ Corp

7. The Olive Young Operating Profile — Why the Asset Matters

For context on why Olive Young drives this much search-engine and investor interest, here is the operating shape (publicly reported / industry-tracked levels):

Korean H&B market share — dominant; rivals Lalavla / Lohbs effectively exited the offline H&B chain category.
Store count — well over 1,300 domestic stores including flagships.
Online channel — Olive Young Online + globalolive.young.co.kr together represent a meaningful and growing share of total revenue.
PB / exclusive brands — wakemake, Bring Green, Round A’Round, biome, and others are Olive Young-incubated and act as both shelf-anchor and margin lever.
Inbound tourism — Olive Young Myeongdong-class flagships are top-3 retail destinations for inbound foreign visitors per multiple tourism boards.
Revenue scale — past the ₩4T-class, with meaningful YoY growth in 2024–2025 cycles (industry-tracked).

In other words: this is an asset that, on its own, would already be one of the larger non-tech KOSPI listings if it were public. That’s the size of the unlisted block sitting inside CJ Corporation’s NAV.

8. Risks to the “Buy CJ Corp for Olive Young” Trade

This trade is not a free option. Specific risks:

Holdco discount stays wide. If Korean Value-Up momentum fades, holdco discounts can stay at 35–50% indefinitely, capping how much Olive Young value flows through to CJ Corp shareholders.
No IPO crystallization. Without a listing, Olive Young’s “marked” value remains an internal accounting figure. Public-market re-rating only happens with a public catalyst (IPO, large secondary, strategic spin-off).
CJ Corp’s other assets dilute. CJ ENM and CJ CheilJedang carry their own cyclical pressures (entertainment cycle, lysine pricing, fx). A bad year at the affiliate level can offset Olive Young’s accretion.
Family-stake overhang. Lee-family direct stakes in Olive Young (separate from CJ Corp’s stake) mean a future IPO has potential family-block secondary supply that markets may price in.
Inbound-tourism beta. Olive Young is structurally exposed to Chinese-visitor recovery; downside scenarios on Korea–China relations affect a real % of the asset’s growth.
Channel disruption. US TikTok / Amazon dynamics could either accelerate (if Olive Young’s globalolive channel scales) or threaten (if independent Korean brands route around Olive Young directly to Western retailers).

9. Final Read

The exact answer to “Is Olive Young publicly traded?” is: No, and the right follow-up question is what you’re actually trying to own.

If you want Olive Young specifically, your only public route is CJ Corporation (000120.KS) — accept the holdco discount, track the IPO timeline, treat the position as a Value-Up + IPO-catalyst combo.
If you want K-beauty as a wave, ignore the search-engine impulse to find an Olive Young ticker and instead build exposure through AmorePacific / LG H&H (brands), Cosmax / Kolmar Korea (ODMs), and Kolmar BNH / COSRX (US-Amazon-bestseller specific).
If you want CJ Group exposure broadly (food, entertainment, logistics, beauty), CJ Corporation again is the single-ticker entry point.
Avoid the common misconception that CJ CheilJedang gives you Olive Young exposure — it doesn’t.

The most underappreciated piece of this whole picture is that Olive Young is materially larger and more profitable than at the 2022 IPO attempt, while CJ Corporation’s holdco discount has not yet meaningfully closed. Whenever the next IPO window opens — whether 2026, 2027, or 2028 — the NAV recognition of Olive Young is a real event for CJ Corporation shareholders.

For now, the cleanest English-search answer is the one we started with: No, Olive Young is not publicly traded. The closest you can get is CJ Corporation (000120.KS).

Appendix — Evidence Tier

[Fact]

CJ Olive Young is not listed on any stock exchange.
CJ Olive Young was carved out from CJ Olive Networks in 2019.
CJ Corporation is the controlling shareholder of CJ Olive Young.
Lee Sun-ho and Lee Kyung-hoo (chairman Lee Jay-hyun’s children) hold direct minority stakes in CJ Olive Young.
A KOSPI IPO filing for CJ Olive Young was withdrawn in 2022.
CJ CheilJedang (097950.KS) is a separate listed entity, with food / bio operations, not a direct shareholder of CJ Olive Young.
AmorePacific (090430.KS), LG H&H (051900.KS), Cosmax (192820.KS), Kolmar Korea (161890.KS), and Kolmar BNH (200130.KS) are listed.

[Inference]

CJ Olive Young’s implied private valuation is materially above the 2022 attempted-IPO range, driven by post-COVID revenue and margin expansion.
The Korean holdco discount on CJ Corporation has historically run 30–50%, capping how much Olive Young’s underlying value flows through to listed CJ Corp shareholders.
A renewed IPO window for Olive Young — whether 2026, 2027, or later — would be a NAV-recognition catalyst for CJ Corp.
ODMs (Cosmax, Kolmar Korea) capture K-beauty wave economics with lower single-brand risk than the heritage-brand names.

[Speculation]

Lee Sun-ho’s direct ~11% stake in CJ Olive Young is a structural incentive for the family / group to eventually monetize via IPO + secondary.
A successful Olive Young IPO at meaningfully higher valuation than 2022 could trigger holdco-discount compression at CJ Corp beyond what fundamental NAV math alone would justify.

[Blocked]

Exact current cap-table of CJ Olive Young (latest financial-investor stake adjustments not always publicly disclosed in full).
Any confirmed 2026 IPO filing date.
Precise gross-margin and operating-margin levels of CJ Olive Young’s PB lines.